- Conditions
- Healthy
- Interventions
- [11C]PF-06427878, PF-06427878 10 mg, PF-06427878 600 mg
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 889–912
of 18,611
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Renal Cell Carcinoma, Recurrent Skin Carcinoma, Stage III Renal Cell Cancer, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer
- Interventions
- Laboratory Biomarker Analysis, Pharmacological Study, Recombinant Human Interleukin-15
- Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 19 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Bethesda, Maryland • Minneapolis, Minnesota + 2 more
- Conditions
- Leukemia, Myeloid, Acute
- Interventions
- DFP-10917, Venetoclax
- Drug
- Lead sponsor
- Delta-Fly Pharma, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 4
- States / cities
- Orange, California • Winston-Salem, North Carolina • Burlington, Vermont + 1 more
- Conditions
- Metastatic Biliary Tract Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal Cancer AJCC v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Stage IVA Colorectal Cancer AJCC v7, Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Fluorouracil, Irinotecan Sucrosofate, Laboratory Biomarker Analysis, Leucovorin Calcium, Rucaparib
- Drug · Other
- Lead sponsor
- Academic and Community Cancer Research United
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota
- Conditions
- Radiation-Induced Parotid Gland Hypofunction, Xerostomia Due to Radiotherapy, Head and Neck Cancer
- Interventions
- AAV2hAQP1: 1 x 10^11 vg/gland (single gland), AAV2hAQP1: 3 x 10^10 vg/gland (both glands), AAV2hAQP1: 3 x 10^11 vg/gland (single gland), AAV2hAQP1: 1 x 10^11 vg/gland (both glands), AAV2hAQP1: 1 x 10^12 vg/gland (single gland), AAV2hAQP1: 3 x 10^11 vg/gland (both glands), AAV2hAQP1: 3 x 10^12 vg/gland (single gland), AAV2hAQP1: 1 x 10^12 vg/gland (both glands)
- Drug
- Lead sponsor
- MeiraGTx UK II Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 5
- States / cities
- Stanford, California • Louisville, Kentucky • Boston, Massachusetts + 2 more
- Conditions
- Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, Chronic Myelomonocytic Leukemia (CMML)
- Interventions
- S227928, Venetoclax
- Drug
- Lead sponsor
- Servier Bio-Innovation LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 5
- States / cities
- Duarte, California • Fairway, Kansas • Grand Rapids, Michigan + 2 more
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Small Intestine Cancer
- Interventions
- anti-thymocyte globulin, filgrastim, cladribine, cyclophosphamide, etoposide, methylprednisolone, tacrolimus, allogeneic bone marrow transplantation, in vitro-treated peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- Up to 45 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides
- Interventions
- Fenretinide
- Drug
- Lead sponsor
- SciTech Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 10
- States / cities
- Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more
- Conditions
- Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Prednisone, Rituximab, Vincristine Sulfate, Vorinostat
- Drug · Other · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2027
- U.S. locations
- 190
- States / cities
- Mobile, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 132 more
- Conditions
- Healthy Subjects, Infection, Human Immunodeficiency Virus
- Interventions
- GSK1349572
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Disseminated Neuroblastoma, Recurrent Neuroblastoma, Regional Neuroblastoma
- Interventions
- monoclonal antibody Ch14.18, isotretinoin, aldesleukin, sargramostim
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Healthy
- Interventions
- CD101 IV, Placebo
- Drug
- Lead sponsor
- Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Aging
- Interventions
- Sirolimus, Metformin, Diclofenac
- Drug
- Lead sponsor
- Anne Chang
- Other
- Eligibility
- 55 Years and older · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Redwood City, California
- Conditions
- Basal Cell Carcinoma of the Skin, Pain, Recurrent Skin Cancer
- Interventions
- methyl-5-aminolevulinate hydrochloride cream, photodynamic therapy, laser therapy
- Drug · Procedure
- Lead sponsor
- Roswell Park Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Healthy
- Interventions
- Olomorasib, Fluconazole
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Daytona Beach, Florida
- Conditions
- Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm
- Interventions
- Azacitidine, Quizartinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Sclerosis
- Interventions
- RPC1063
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Long Beach, California • San Francisco, California • Raleigh, North Carolina + 3 more
- Conditions
- Breast Cancer
- Interventions
- gemcitabine hydrochloride, pegylated liposomal doxorubicin hydrochloride
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Prolymphocytic Leukemia
- Interventions
- Acalabrutinib
- Drug
- Lead sponsor
- Acerta Pharma BV
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • New Hyde Park, New York • New York, New York + 5 more
- Conditions
- Healthy Volunteers
- Interventions
- Febuxostat XR, Maalox Advance Regular Strength liquid
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Advanced Solid Tumors
- Interventions
- BMS-986482, Pumitamig
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 286 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- Irvine, California • Los Angeles, California • Aurora, Colorado + 4 more
- Conditions
- Solid Tumours
- Interventions
- Debio1347 (CH5183284)
- Drug
- Lead sponsor
- Debiopharm International SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL
- Interventions
- Sonrotoclax, Zanubrutinib
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 6
- States / cities
- Tampa, Florida • Fort Wayne, Indiana • Westwood, Kansas + 3 more
- Conditions
- Healthy
- Interventions
- PLX5622, Placebo
- Drug
- Lead sponsor
- Plexxikon
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota